Zydus Cadila gets tentative nod from USFDA to market cancer drug

"Ibrutinib belongs to a class of drugs known as kinase inhibitors and is used to treat certain cancers, such as mantle cell lymphoma or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and Waldenstrom's macroglobulinemia," Zydus Cadila said.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news